MEI Pharma (MEIP) Stock Price, News & Analysis

Company Overview

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $2.65 to $2.80
• 50-Day Range: $2.04 to $2.84
• 52-Week Range: $1.46 to $4.10
• Volume: 8,218 shs
• Average Volume: 44,307 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

MEI Pharma Stock Analysis - MarketRank™

MEI Pharma scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for MEI Pharma.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MEI Pharma are expected to grow in the coming year, from ($5.10) to ($3.71) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MEI Pharma is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MEI Pharma is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MEI Pharma has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of MEI Pharma has been sold short.

Short Interest Ratio / Days to Cover

MEI Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MEI Pharma has recently decreased by 51.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MEI Pharma does not currently pay a dividend.

Dividend Growth

MEI Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.09

Percentage of Shares Shorted

0.02% of the float of MEI Pharma has been sold short.

Short Interest Ratio / Days to Cover

MEI Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MEI Pharma has recently decreased by 51.85%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for MEI Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MEI Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.12% of the stock of MEI Pharma is held by insiders.

Percentage Held by Institutions

52.38% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MEIP Stock Analysis - Frequently Asked Questions

How have MEIP shares performed this year?

MEI Pharma's stock was trading at $2.46 on January 1st, 2025. Since then, MEIP stock has increased by 9.3% and is now trading at $2.69.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.39) earnings per share for the quarter.

When did MEI Pharma's stock split?

MEI Pharma's stock reverse split on the morning of Monday, April 17th 2023.The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of MEI Pharma?

Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MEI Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MEI Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), CymaBay Therapeutics (CBAY) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 9/17/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MEIP
• Previous Symbol: NASDAQ:MSHL
• CIK: 1262104
• Web: www.meipharma.com
• Phone: (858) 369-7100
• Fax: 302-655-5049
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $17.78 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -77.00%
• Return on Assets: -64.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.78
• Quick Ratio: 16.78

Sales & Book Value

• Annual Sales: $65.30 million
• Price / Sales: N/A
• Cash Flow: $5.85 per share
• Price / Cash Flow: 0.46
• Book Value: $4.96 per share
• Price / Book: 0.54

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: 0.19